business

H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

Yahoo Finance · Jun 17, 2026, 3:55 PM · Also reported by 4 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com UBS reiterates Celldex Therapeutics stock rating on trial data Investing.com UBS reiterates Denali Therapeutics stock rating citing Avlayah launch Investing.com Leerink reiterates Edgewise Therapeutics stock rating on trial data Investing.com Barclays reiterates Underweight rating on CarMax stock at $31

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

Also covered by

More in business